Atlantic Coastal Acquisition Corp II
ACAB

$11.22

0.36%

Market Cap: $91.6M

About: Atlantic Coastal Acquisition Corp II is a blank check company.

Employees: 4

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,686 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

7% more capital invested

Capital invested by funds: $6.22M [Q1] → $6.67M (+$453K) [Q2]

1.8% more ownership

Funds ownership: 5.3% [Q1] → 7.09% (+1.8%) [Q2]

0% more funds holding

Funds holding: 8 [Q1] → 8 (+0) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ACAB.

See Analyst Rankings

Financial journalist opinion

Atlantic Coastal Acquisition Corp. II Receives Notification of Deficiency from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

NEW YORK, June 13, 2024 /PRNewswire/ -- Atlantic Coastal Acquisition Corp. II (NASDAQ: ACAB) (the "Company"), a special purpose acquisition company, announced that it had previously received written notification (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on June 3, 2024 that, because the Company had not yet filed its Quarterly Report on Form 10-Q for the three month period ended March 31, 2024 (the "10-Q") with the Securities and Exchange Commission (the "SEC"), the Company was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1). The Notice has no immediate effect on the listing of the Company's securities on Nasdaq.

Atlantic Coastal Acquisition Corp. II Receives Notification of Deficiency from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

See News Rankings